FDA Grants Fast Track Designation to Precision BioSciences' DMD Gene Therapy
Precision BioSciences receives FDA Fast Track designation for PBGENE-DMD, a gene editing therapy for Duchenne muscular dystrophy designed to treat patients with mutations in exons 45-55.